(CRSP) Crispr Therapeutics - Ratings and Ratios

CRISPR Therapeutics AG (NASDAQ:CRSP) is a pioneering biotechnology company specializing in gene editing and gene-based therapies. Leveraging its proprietary CRISPR/Cas9 platform, the firm develops precision medicines targeting severe genetic disorders. The CRISPR/Cas9 system enables highly specific modifications to genomic DNA, offering transformative potential for treating devastating diseases.

The companys therapeutic pipeline spans multiple disease areas, including hemoglobinopathies, immuno-oncology, and type 1 diabetes. Its lead product, CASGEVY (ex vivo CRISPR/Cas9 gene-edited cell therapy), addresses transfusion-dependent beta-thalassemia and severe sickle cell disease by editing hematopoietic stem cells to produce fetal hemoglobin. Additional pipeline highlights include allogeneic CAR T cell therapies, in vivo gene editing programs for cardiovascular diseases, and CTX211, a stem cell-derived candidate for type 1 diabetes.

CRISPR Therapeutics has established strategic collaborations with Vertex Pharmaceuticals, Nkarta, and Capsida Biotherapeutics, enhancing its capabilities in cell therapy, gene editing, and viral vector technologies. The company was founded in 2013 and is headquartered in Zug, Switzerland.

Based on the technical and fundamental data, the 3-month forecast for CRSP suggests potential volatility. The stock is trading below its SMA 50 and SMA 200, indicating bearish momentum. However, the ATR of 2.25 suggests moderate volatility. With a forward P/E of 23.36 and a high P/S ratio of 90.80, the market reflects expectations for long-term growth despite current losses (RoE: -18.96%).